UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

British journal of clinical pharmacology, 2017-11, Vol.83 (11), p.2367-2376

2017

Volltextzugriff (PDF)

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results

PloS one, 2023-07, Vol.18 (7), p.e0288271-e0288271

2023

Volltextzugriff (PDF)

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

The Lancet (British edition), 2010-10, Vol.376 (9751), p.1467-1475

2010

Volltextzugriff (PDF)

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study

Clinical and translational science, 2022-11, Vol.15 (11), p.2663-2672

2022

Volltextzugriff (PDF)

Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders

Clinical and translational science, 2020-09, Vol.13 (5), p.830-834

2020

Volltextzugriff (PDF)

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Clinical and translational science, 2022-02, Vol.15 (2), p.442-450

2022

Volltextzugriff (PDF)

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants

Clinical and translational science, 2023-07, Vol.16 (7), p.1210-1219

2023

Volltextzugriff (PDF)

Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection

Antimicrobial Agents and Chemotherapy, 2007-10, Vol.51 (10), p.3574-3581

2007

Volltextzugriff (PDF)

Dosing will be a key success factor in repurposing antivirals for COVID‐19

British journal of clinical pharmacology, 2021-09, Vol.87 (9), p.3451-3454

2021

Volltextzugriff (PDF)

A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects

Clinical and translational science, 2022-06, Vol.15 (6), p.1507-1518

2022

Volltextzugriff (PDF)

Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval

Clinical pharmacology and therapeutics, 2024-09, Vol.116 (3), p.518-521

2024

Volltextzugriff (PDF)

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

EBioMedicine, 2016-03, Vol.5 (C), p.147-155

2016

Volltextzugriff (PDF)

Biodiversity and agriculture: Production frontiers as a framework for exploring trade-offs and evaluating policy

Environmental science & policy, 2012-11, Vol.23, p.85-94

2012

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment

Journal of clinical lipidology, 2022-03, Vol.16 (2), p.208-219

2022

Volltextzugriff (PDF)

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

Clinical pharmacokinetics, 2015-05, Vol.54 (5), p.537-549

2015

Volltextzugriff (PDF)

Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo

Clinical pharmacology and therapeutics, 2023-02, Vol.113 (2), p.298-309

2023

Volltextzugriff (PDF)

Module Theory, Extending Modules and Generalizations

1, 2016

Volltextzugriff (PDF)

Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics

Antimicrobial Agents and Chemotherapy, 2013-08, Vol.57 (8), p.3470-3477

2013

Volltextzugriff (PDF)

Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics

British journal of clinical pharmacology, 2021-09, Vol.87 (9), p.3398-3407

2021

Volltextzugriff (PDF)

Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype

Antimicrobial Agents and Chemotherapy, 2008-04, Vol.52 (4), p.1533-1537

2008

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor

Clinical therapeutics, 2014-12, Vol.36 (12), p.2047-2063.e3

2014

Volltextzugriff (PDF)

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

Clinical pharmacokinetics, 2001, Vol.40 (12), p.893-905

2001

Volltextzugriff (PDF)

Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin

Clinical pharmacokinetics, 2013-09, Vol.52 (9), p.805-813

2013

Volltextzugriff (PDF)

Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future

Clinical pharmacology and therapeutics, 2021-04, Vol.109 (4), p.867-891

2021

Volltextzugriff (PDF)

Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir

Clinical infectious diseases, 2006-12, Vol.43 (Supplement-4), p.S235-S246

2006

Volltextzugriff (PDF)

1 – 25 von 2.169

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.914)
Mit Volltextzugriff
(1.808)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.467)
Life Sciences & Biomedicine
(1.050)
Humans
(883)
Female
(511)
Male
(455)
Biological And Medical Sciences
(309)
Physical Sciences
(298)
Adult
(289)
Middle Aged
(286)
Medical Sciences
(262)
Animals
(228)
Aged
(223)
Risk Factors
(145)
Science & Technology - Other Topics
(134)
Adolescent
(127)
Genetics & Heredity
(122)
Multidisciplinary Sciences
(120)
Technology
(114)
Genomes
(110)
Medicin Och Hälsovetenskap
(104)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study

Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants

Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection

Dosing will be a key success factor in repurposing antivirals for COVID‐19

A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects

Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

Biodiversity and agriculture: Production frontiers as a framework for exploring trade-offs and evaluating policy

Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo

Module Theory, Extending Modules and Generalizations

Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics

Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics

Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype

Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin

Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future

Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir

Suchergebnisse filtern